Kornimate/medical-research-clean huggingface dataset:
comparison of coronally advanced lingual flap to modified mpi for flap advancement in partially edentulous patients

Conditions: Alveolar Bone Loss

Summary: comparison of cronally advanced lingual flap to modified periosteal releasing incision (mpri)

clinical assessment and comparison of coronally advanced lingual flap to modified periosteal releasing incision for flap advancement in partially edentulous patients undergoing guided bone regeneration using titanium mesh: a randomized clinical trial

Eligibility criteria:
inclusion criteria: * partially edentulous patients in the mandibular posterior region. * patients with healthy systemic condition. * insufficient ridge width (\< 5mm). * presence of proper inter-arch space for placement of the implant prosthetic part. * adequate soft tissue biotype (≥ 2 mm). exclusion criteria: * patients with systemic conditions that may interfere with the results of the study. * patients with local pathological defects related to the area of interest. * unmotivated, uncooperative patients with poor oral hygiene. * patients with habits that may jeopardize the implant longevity and affect the results of the study such as smoking, alcoholism or para-functional habits.

Keywords: ridge augmentation titanium mesh flap advancement
prevention and treatment with hydroxychloroquine + azithromycin of acute respiratory syndrome induced by covid-19

Conditions: Acute Respiratory Distress Syndrome; Covid19

Summary: multi-centered, randomized, open label clinical trial to study the safety and effectivity of hydroxychloroquine + azithromycin to treat covid-19 symptoms in primary care patients.

in the patient group treated with hydroxychloroquine + azithromycin we expect to find a diminution of 20% or more regarding the evolution of acute respiratory syndrome, as opposed to patients who have not been treated with these medicines. to date, there is no shown effective treatment regime for acute respiratory distress caused by covid-19.

Eligibility criteria:
inclusion criteria: * patients with positive semi-quantitative pcr and covid19 symptoms (fever, cough, diarrhea, dyspnoea, loss of smell). * signed informed consent exclusion criteria: * retinal degeneration. * congenital or acquired long qt syndrome. * advanced liver failure. * renal insufficiency (incompatible with creatinine clearance less than 50 ml /minute). * allergic to hydroxychloroquine or azithromycin. * serious interaction with the drugs used. * pregnant or breastfeeding. * men and women in fertile and sexually active periods, who do not accept a highly effective contraceptive method. * inability to follow study procedures.

Keywords: acute respiratory syndrome sars-cov-2 covid19 hydroxychloroquine azithromycin covid19 symptoms
to explore a bridging index for the effectiveness of the clinical trial

Conditions: Randomized

Summary: to explore a bridging index for the effectiveness of the clinical trial with nasal spray lyophilized live attenuated influenza vaccine

with a randomized, blind, parallel placebo-controlled design, to screen the susceptible individuals aged 3\~59 years old whose titers of either of hi antibody level of h1n1, h3n2 or b are not higher than 1:10 prior immunization , in which all persons are to be assigned into the two subgroups (aged 3\~17 and 18\~59 years old) with radio of 1:1, individually. all persons of each age subgroups are to be randomly assigned into the two groups (vaccine or placebo group) with th radio of 2:1 via intranasal injection of one dose of the study vaccine or placebo. the blood samples are to be collected prior immunisation and on the 21st day post immunisation, individually, the nasopharyngeal swab samples are also to be done prior immunisation and on the 10th day and 21st day post immunisation, individually, and the levels of serum hi antibody and mucous siga antibody are to be compared between the two groups, respectively.

Eligibility criteria:
inclusion criteria: 1. healthy volunteer aged 3\~59 years old； 2. no vaccination with any influenza vaccine within the past year； 3. no catching any influenza or flu like symptoms （axillary temperature ≥ 38℃， accompanied by cough or sore throat ）； 4. influenza susceptible individual（any serum hi antibody level of h1n1, h3n2 and b≦1:10）； 5. with informed consent obtained from the volunteer and / or guardian； 6. willing of volunteers and / or guardians to comply with the requirements of the clinical trial protocol. exclusion criteria: 1. known allergy individual to any ingredient of this product, including egg protein, subsidiary material and/or gentamycin sulfate; 2. patients with acute disease, severe chronic disease, acute attack of chronic disease and/or fever (axillary temperature ≥ 37.3℃ on the day of immunisation); 3. pregnancy (enquire); 4. patients with leigh syndrome treated with aspirin or aspirin containing drugs; 5. patients with immunodeficiency or receiving immunosuppressive therapy; 6. patients with uncontrolled epilepsy and other progressive nervous system diseases, with a history of guillain barre syndrome; 7. patients with rhinitis or other nasal abnormalities judged by clinicians that may affect vaccination or sample collection; 8. accept any immunoglobulin and / or any blood products within 3 months, or plan to use them during the study (until post immunization blood sample collection); 9. .taking anti influenza drugs in the past 48 hours; 10. .any situation that the researchers believe may affect the study.

Keywords: influenza vaccine nasal spray
paracetamol discontinuation in the elderly after long-term consumption

Conditions: Pain, Chronic; Pain, Medication; Pain, Discontinuation

Summary: to investigate if long-term treatment of paracetamol can be discontinued without no worsening on pain, health-related quality-of-life and level of function compared to continuing paracetamol treatment in patients aged 65 years or more.

aim: to investigate if long-term treatment of paracetamol can be discontinued without worsening on pain, health-related quality-of-life and level of function compared to continuing paracetamol treatment in patients aged 65 years or more. trial design: patients are randomized to either arm 1: standard care (paracetamol continuation) or arm 2: experimental treatment (placebo). the investigation is double-blinded. patients are screened and recruited from department of respiratory medicine at copenhagen university hospital bispebjerg. patients with a daily consumption of 3 grams or more of prescribed paracetamol and who comply with the other eligibility criteria will be invited to participate in the trial and asked for written, informed consent. if given we collect data regarding the patient's medications, any medication changes during the intervention and followup, frailty (frail scale), self-reported history of falls, recent admissions, self-reported health-related quality of life (eq-5d-5l), level of function tested by hand grib strength and sitting-rising test, and death. data is collected at baseline and after 2 weeks when ending treatment intervention, and a 26 week follow-up.

Eligibility criteria:
inclusion criteria: * 65 years or more * regular daily users of 3 to 4 grams of paracetamol for at least 6 months prior to enrollment exclusion criteria: * malignant pain cf. their medical records * patients using other regular analgesics cf. indication on prescription * patients receiving paracetamol tablets with modified release or sustained release * patients in warfarin treatment * patients with terminal illnesses, cf. their medical records. * patients receiving dosages dispensed by their pharmacy * mini-mental state examination (mmse) score less than 25 * patients with or suspected to have covid-19.
exploring the role of magnesium in rest cramps

Conditions: Rest Cramps

Summary: this study sets out to show whether infusions of magnesium can lessen the frequency of rest cramps and to determine whether rest cramp sufferers have a deficiency in magnesium.

subjects will be randomized to receive 5 days of 4 hour iv infusions of d5w either with or without 20 mmol magnesium sulfate added. twenty four hour urinary excretion of magnesium will be determined on the first day of infusions to assess whether magnesium deficiency is present. ten normal controls will also undergo a single infusion and collection of urine to serve as a comparison group for the urinary excretion data.

Eligibility criteria:
inclusion criteria: * ≥2 leg or foot cramps per week in a 4 week run-in diary exclusion criteria: * egfr\<50 * neurologic disease * pregnancy * heart block * bradyarhythmia without pacemaker * digoxin use * liver disease * addison's disease * history of mi * chf * absence of detectable reflexes

Keywords: magnesium infusion magnesium sulfate rest cramps nocturnal leg cramps muscle cramps fractional urinary excretion urinary excretion 24 hour urine serum magnesium magnesium deficiency family practice general practice richmond cramp frequency magnesium status urinary magnesium cramp diary sf 36
low-dose radiotherapy for diffuse large b-cell lymphoma

Conditions: Lymphoma

Summary: patients with diffuse large b-cell lymphoma with indication for palliative radiotherapy are treated with low-dose radiation (2 x 2 gy) to the symptomatic sites only. the primary endpoint of the study is the response rate and quality of life of the patients (qol).

response is planned at 21-day after completion of the treatment. response assessment is based on the standard definitions of the world health organization using complete response (cr), partial response (pr), stable disease (sd), and progressive disease (pd) as response assessment criteria. the efficacy of the treatment consisted of a reduction greater than 50% of the maximum diameter of the radiated mass (pr + cr). qol is evaluated using the european organization for research and treatment of cancer (eortc) qlq-c30 3.0 version questionnaire. the qlq-c30 questionnaire is self administered to the patients at baseline and at 21 days after treatment.

Eligibility criteria:
inclusion criteria: * patients with histologically proven diagnosis of dlbcl with indication for palliative radiotherapy exclusion criteria: * none

Keywords: large b-cell diffuse
increasing availability of lower energy meals vs. menu energy labelling on food choice

Conditions: Nutrition Poor; Obesity; Diet, Healthy; Food Selection

Summary: two randomized control trials examining human food choice (i.e. selection of high energy 'unhealthy' foods vs. selection of healthier foods). interventions: in a between-subjects design, participants (recruitment stratified by socioeconomic position) made food choices (main dish, plus optional sides and desserts) in the absence vs. presence of menu energy labelling and from menus with baseline (10%) vs. increased availability (50%) of lower energy main dishes. main outcome measures: average energy content (kcal) of main dish chosen and average total energy content of all food ordered, including optional sides and desserts.

see attached protocol documents.

Eligibility criteria:
inclusion criteria: * participants were eligible to participate if they were us residents, aged of 18 or above, fluent in english, had access to a computer with an internet connection and had no dietary restrictions exclusion criteria: * see above. stratification criteria: - we aimed to recruit a sample stratified by gender (approx. 50/50) and highest educational qualification (approx. 40% high school or less, 60% above high school) to be broadly representative of us adults.
endoprosthesis metal toxicity study

Conditions: Bone Tumor; Cancer of Bone; Heart Diseases; Cognitive Impairment; Cognitive Decline; Chemotherapy Effect; Memory Problem

Summary: the purpose of this research is to investigate whether patients who previously had endoprosthesis surgery experience memory, thinking, or heart problems. it will also help determine how often these problems occur.

at your first visit you will be asked to do the following: 1. sign the consent document. 2. patient interview: an interview will be conducted by the study coordinator on the research team. they will ask your past surgical history, health history, medications, and your cognition. 3. informant interview: a close friend, spouse of relative of you will be interviewed about your day-day cognition. 4. memory interview: you will be evaluated on your memory and thinking skills three total times. one to determine baseline, and then repeated at one year and two years. you will answer questions that evaluate various thinking abilities such as concentration, memory, reasoning, and learning. 5. blood draw: you will have a blood draw three times (4.2-5 tablespoons) to determine your baseline, 1 year, and 2 year research results. 6: echocardiogram: you will be asked to have three echocardiograms. one to determine baseline, and then repeated at one year and two years.

Eligibility criteria:
inclusion criteria: * patient has an endoprosthesis after extremity malignancy exclusion criteria: * current fracture or infection around the endoprosthesis * patient is pregnant

Keywords: endoprosthesis metallosis toxicity
vascular structure, vascular function and vascular aging in adults diagnosed with persistent covid

Conditions: Persistent COVID-19; Quality of Life; Lifestyles; Arterial Stiffness

Summary: the icoper study aims to analyze the structure, vascular function, vascular aging and determining factors in 300 adults diagnosed with persistent covid in the field of primary health care.

objective: to analyze the structure, the vascular function, the vascular aging and the determining factors in adults with a diagnosis of persistent covid and the differences by gender. design: cross-sectional descriptive observational study. setting: the study will be carried out at the salamanca primary care research unit (apisal). study subjects: the study includes the basis of the persistent covid monographic consultation in the internal medicine service of the university hospital of salamanca and the subjects with the diagnosis of persistent covid in the medora primary care clinical history. thus, 300 subjects have been obtained who are diagnosed with persistent covid, who meet the diagnostic criteria established by the spanish society of general and family physicians and sign the informed consent. measurements: the variables reflected in the integrated assistance process for the care of people affected by sars cov-2 of the junta de castilla y león will be collected, to evaluate the functional status of the patient and persistent symptoms, their impact on activities of daily life and quality of life of patients with persistent covid and the perception of their health. lifestyles (diet, physical activity, tobacco and alcohol), psychological factors and cognitive impairment will be collected using validated questionnaires, and physical activity will be objectively measured with a 7-day pedometer. vascular structure and function will be analyzed by measuring the thickness of the carotid intima media (sonosite micromax); pulse wave analysis and carotid-femoral pulse wave velocity (vopcf) (sphygmocor system). cardio ankle vascular index (cavi), ankle-brachial pulse wave velocity (vopbt) and ankle-brachial index (vasera vs-2000®). vascular aging will be calculated using the 10 and 90 percentiles of the vopcf and the vopbt. demographic, analytical variables and to assess retinal, cardiac, renal, cerebral vascular lesion and cardiovascular risk will be collected.

Eligibility criteria:
inclusion criteria: * history of probable or confirmed sars-cov-2 infection, usually 3 months after onset, with symptoms that last at least 2 months and cannot be explained by an alternative diagnosis. * common symptoms should include fatigue, shortness of breath, and cognitive dysfunction, and an impact on daily functioning. exclusion criteria: * subjects in a terminal situation. * inability to travel to health centers. * presenting a history of cardiovascular disease (ischemic heart disease or cerebrovascular disease). * glomerular filtration rate of less than 30%.
a drug monitoring study on peg-asparaginase treatment in children diagnosed acute lymphoblastic leukaemia

Conditions: Acute Lymphoblastic Leukaemia

Summary: asparaginase is an important drug i the treatment of childhood leukaemia. the aim of this project is to study the pharmacokinetics, pharmacodynamics and antibody development and hypersensitivity reactions during prolonged peg-asparaginase treatment. study part 1) asparaginase pharmacokinetics and pharmacodynamics during prolonged peg-asparaginase treatment: a nopho all-2008 study study part 2) asparagine depletion in cerebrospinal fluid: a nopho all-2008 study study part 3) a characterization of peg-asparaginase hypersensitivity in children treated according to the nopho all 2008 protocol perspectives: new knowledge about peg-asparaginase treatment regarding dosing, dosing interval, adverse effects and efs, which may lead to improved future therapy patients: children diagnosed with acute lymphoblastic leukaemia in the nordic countries


Eligibility criteria:
inclusion criteria: children aged between 1 and 18 years old, diagnosed all and treated according to the nopho-all 2008 protocol and who have accepted to participate in this study exclusion criteria: children that does not attend the nopho-all 2008 protocol but receives standard treatment

Keywords: peg-asparaginase children pharmacokinetics antibodies acute lymphoblastic leukaemia adverse effects
isokinetic strength training in hemiparetic patient with knee extension thrust

Conditions: Hemiparesis/Hemiplegia (One Sided Weakness/Paralysis); Gait Disorder

Summary: the purpose of this study is to assess the impact of an isokinetic strength training of knee flexor and extensor muscles on walking performance in hemiparetic patients with knee extension thrust.

the study will be interventional single case experimental design (sced) with multiple baseline design. sced are experimental designs aiming at testing the effect of an intervention using a small number of patients using repeated measurements, sequential and randomized introduction of an intervention and method-specific data analysis, including visual analysis and specific statistics. during baseline, patients will have a rehabilitation program in day hospital (4 days per week) with physiotherapy and physical activity and if necessary occupational and speech therapy. isokinetic strength training will be added to this conventionnal rehabilitation program and will begin after 3, 4 or 5 weeks of baseline according to randomization 12 patients will be included in this study (6 patients in subacute stage and 6 in chronic stage ).

Eligibility criteria:
inclusion criteria: * hemiparetic patient (hemorragic or ischemic stroke) * subacute stage (\ 6 months) (6 patients in each group) * age between 18 and 75 years * able to walk 10 meters independently without any assistive devices * knee extension thrust during stance phase of gait cycle (rapid posterior movement of the knee toward extension) * scheduled rehabilitation program with isokinetic strength training * affiliation to a social security * patients who received and signed informed consent exclusion criteria: * major comprehension deficit that not allow to give informed consent and participate to isokinetic strength training (assessed with comprehension subscore of langague screening test) * non stable (unstable cardiovascular condition) * musculoskeletal disorders with knee pain that not allowed isokinetic strength training * botulinum toxin injection less than 3 months or repeated injection in lower limb, * proprioception trouble assessed with proprioception section of the fugl-meyer assessment \[fma-p\] 0/2 * spasticity of triceps surae ≥2 (modified ashworth scale) * ankle dorsiflexion angle less than 90° * pregnant women or breastfeeding * persons with safety measure

Keywords: stroke extensor thrust resistance training isokinetic walking speed rehabilitation
growth hormone (gh) deficiency & insulin like growth factor 1 (igf-i)/ insulin like growth factor binding protein 3 (igfbp-3) ratio

Conditions: Diagnosis of GHD With IGF-I/IGFBP-3 Ratio

Summary: a 35-month cross-sectional observational study was conducted at an outpatient university hospital in amman, jordan. we obtained a comprehensive medical and laboratory evaluation for 134 short-statured children (64 boys and 70 girls, aged 4-16 years). complete and partial growth hormone deficincy (ghd) were defined as peak forwth hormone (gh) response of 5 and 7 ng/ml \[irma/ diasorin®\], respectively in both clonidine stimulation and insulin tolerance tests. serum igf-i, igfbp-3 and igf-i/igfbp-3 ratio were determined for all participants.


Eligibility criteria:
inclusion criteria: * children presented to jordan univeristy hospital (juh) outpatient endocrinology clinic for the evaluation of short stature (ss) exclusion criteria: (i) their parents could not provide written consent for them; (ii) they were lost to follow up; (iii) they could not perform clonidine stimulation tests (cst) or insulin tolerance test (itt) due to a medical contraindication (e.g. cardiac disorder, seizure disorder); (iv) they had received gh therapy in the past; (v) they were known to have pituitary diseases, hypothyroidism, hypogonadism or discovered to have panhypopituitarism or (vi) they have malnutrition, diabetes mellitus, liver disease, or other chronic illnesses.
mechanism study to investigate difference in efficacy of neoadjuvant chemoimmunotherapy in lung squamous cell carcinoma

Conditions: Tumor Microenvironment; Lung Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy

Summary: to explore mechanisms of immunotherapy resistance and relation to changes in the tme before and after pd-1 blockade combined with chemotherapy

the biobank of thoracic surgery department of tangdu hospital collected pre-treatment tissues from patients during endoscopy. the investigators retrospectively summarized the clinical characteristics of these patients and patients with operable locally advanced lung squamous cell carcinoma were selected and followed. the investigators plan to employ snrna-seq and scrna-seq respectively to profile 20 samples of paired pre-treatment and post-treatment tumors from ten patients (discovery cohort) to create a cell atlas for analysis, and spatial transcriptomics to examine 8 samples from four patients. in discovery cohort, estimated 5 patients achieve major pathological response (mpr) and 5 patients achieve non-mpr after nicb. after analyzing the results of discovery cohort, the investigators will collect frozen tissues and formalin-fixed, paraffin-embedded (ffpe) tissue from our biobank for bulk rna-seq analysis or immunohistochemistry (ihc) staining as validation cohort to further investigate the predictive value and biological significance of our markers.

Eligibility criteria:
inclusion criteria: 1. aged 40 to 80 years; 2. had histologically confirmed lusc with operable locally advanced stage 3. no prior anti-tumor therapy; received neoadjuvant immunotherapy consisting of three cycles of anti-pd-1 icb plus nab-paclitaxel and carboplatin 4. pre-treatment tissues exclusion criteria: 1. the presence of central nervous system metastases 2. the presence of immunodeficiency disease; previous therapies with immunosuppressants within 14 days prior to the initiation of study treatment; 3. uncontrolled hypertension 4. history of or having pulmonary fibrosis or interstitial lung disease